Whooping Cough Diagnostics Market size was valued at USD x billion in 2021 and is expected to grow at a CAGR of x% from 2022 to 2028. whooping cough diagnostics market is growing at significant rates owing to the prevalence of pertussis. Market players are focusing on new product developments, acquisitions, partnerships, and collaborations. There are many products that are under clinical trials. Whooping cough is also called pertussis. It is an infection of the respiratory system caused by the bacterium Bordetella pertussis. It mainly affects babies younger than 6 months old who are not yet protected by immunizations and kids 11 to 18 years old whose immunity has started to fade. The market is expected to experience is lucrative growth during the forecast period globally owing to the ongoing clinical trials and chances of many nearby approvals. For Instance, in 2014, Quidel Corporation received U.S FDA clearance to market its AmpliVue Bordetella Assay for the detection of Bordetella pertussis nucleic acids and In November 2015, Meridian Bioscience received U.S FDA clearance for new claims for its illumigene Pertussis molecular amplification test.
In May 2017, Great Basin Scientific, Inc. launched its Bordetella Direct Test in S and its CE marking designation under European Directive on In-vitro Diagnostic Medical Devices.
In May 2017, Luminex received U.S.FDA clearance for its Aries Bordetella Assay for direct detection pf bordetella pertussis and Bordetella parapertussis.